Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY)

NCT04339595 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT04339595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04339595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV Interventional Study to Assess the Disease-Modifying Effect of Long-Term Treatment With Tildrakizumab in Adult Patients With Moderate-To-Severe Plaque Psoriasis (MODIFY)
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Terminated
Start date
January 29, 2020
Completion date
July 31, 2020
Enrollment
47 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis